key: cord-1016397-tcmdl01x authors: Peng, P.; Hu, J.; Deng, H.-j.; Liu, B.-z.; Wang, K.; Tang, N.; Huang, A.-L. title: Changes of Humoral Immunity Response in SARS-CoV-2 Convalescent Patients over 8 months date: 2020-11-09 journal: nan DOI: 10.1101/2020.11.06.20227439 sha: da0be8dcea7c0c257921f70405b479a897978116 doc_id: 1016397 cord_uid: tcmdl01x Many countries around the world have all seen a sharp rise in COVID-19 cases as the second wave since the beginning of October 2020. Decline of antibodies response to severe acute respiratory syndrome coronavirus (SARS-CoV-2) that was reported exclusively in the early month increases the risk of reinfection for convalescent individuals. There is a current need to follow the maintenance of special antibodies against SARS-CoV-2. Here, we reported changes of antibodies against SARS-CoV-2 in convalescent patients over 8 months. Antibodies of all 20 participants targeting SARS-CoV-2 spike receptor binding-domain (RBD) had decreased from a mean OD450 value 1.78 to 0.38 over 8 months. The neutralizing antibody (NAb) titers decreased from the mean ID50 value 836 to 170. The NAb titers were significantly correlated with IgG level during 8 months (P<0.001). Furthermore, while RBD-specific IgG existence of 25% (5/20) convalescent plasma was undetectable, the NAb titers of 15% (3/20) convalescent plasma decreased below the threshold. In addition, compared to wild-type SARS-CoV-2 (S-D614), lower titers of neutralizing antibodies against its G614 variant were shown at 8 months after symptom onset. This study has important implications when considering antibody protection against SARS-CoV-2 reinfection. 1 . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted November 9, 2020. ; https://doi.org/10.1101/2020.11.06.20227439 doi: medRxiv preprint NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. Many countries around the world have all seen a sharp rise in COVID-19 cases as the second 2 wave since the beginning of October 2020. Decline of antibodies response to severe acute 3 respiratory syndrome coronavirus (SARS-CoV-2) that was reported exclusively in the early 4 month increases the risk of reinfection for convalescent individuals. There is a current need to 5 follow the maintenance of special antibodies against SARS-CoV-2. Here, we reported 6 changes of antibodies against SARS-CoV-2 in convalescent patients over 8 months. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted November 9, 2020. ; https://doi.org/10.1101/2020.11.06.20227439 doi: medRxiv preprint Twenty patients who had recovered from COVID-19 were included in our cohort (see Table) . Blood samples were obtained in February and October with correspond to a median of 25 20 days (range 5 to 33 days) and 230 days (range 221 to 248 days) after symptom onset ( Figure 21 A). Enzyme-linked immunosorbent assay (ELISA) was performed to evaluate the presence of The neutralizing antibodies (NAbs) were measured by SARS-CoV-2 wild-type (S-D614) and S-G614 mutant pseudovirus-based assays in 293T-ACE2 cells. The inhibitory dose (ID50) was 26 calculated as the titers of NAbs. Antibodies of all 20 participants targeting SARS-CoV-2 spike RBD had decreased from a Among them, NAb titers of 3 participants (15%) were lower than the threshold at 8 months is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted November 9, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted November 9, 2020. ; https://doi.org/10.1101/2020.11.06.20227439 doi: medRxiv preprint Meanwhile, there are limitations to our study on the lack of correlation analysis between 63 clinical characteristics and specific antibody levels due to the small sample size, as well as on 64 the lack of data to evaluate anamnestic immune response. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted November 9, 2020. ; https://doi.org/10.1101/2020.11.06.20227439 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted November 9, 2020. ; https://doi.org/10.1101/2020.11.06.20227439 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted November 9, 2020. ; https://doi.org/10.1101/2020.11.06.20227439 doi: medRxiv preprint SARS-coronavirus-2 strain confirmed by whole genome sequencing. Clinical infectious 92 diseases. 2020. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted November 9, 2020. ; https://doi.org/10.1101/2020.11.06.20227439 doi: medRxiv preprint Enable Surveillance of Low Prevalence Communities and Reveal Durable Humoral Immunity Change in antibodies to SARS-CoV-2 over 82 60 days among health care personnel in Longitudinal dynamics of the neutralizing antibody 84 response to SARS-CoV-2 infection Quick COVID-19 Healers Sustain Anti-SARS-CoV-2 Antibody Production COVID-19 re-infection by a phylogenetically distinct take responsibility for the integrity of the data and the accuracy of the data analysis. Concept and design: Ai-long Huang, Ni Tang, Kai Wang, Pai Peng, Jie Hu. Acquisition, analysis, or interpretation of data: All authors. Drafting of the manuscript: Pai Peng. Critical revision of the manuscript for important intellectual content: All authors. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprintThe copyright holder for this this version posted November 9, 2020. ; https://doi.org/10.1101/2020.11.06.20227439 doi: medRxiv preprint